Arcutis Biotherapeutics gets ZORYVE FDA approval for seborrheic dermatitis
Arcutis Biotherapeutics, Inc., a pioneer in immuno-dermatology, has announced the U.S. Food and Drug Administration’s (FDA) approval of their new drug application for ZORYVE (roflumilast) topical foam, 0.3%, aimed at treating seborrheic dermatitis in individuals aged 9 years and older. This approval marks a significant advancement in dermatological care, with ZORYVE being the first drug […]